Evaluación clínica de los resultados de salud tardíos en sobrevivientes de tumor de Wilms
Topic overview
Clinical evaluation of long-term health outcomes in Wilms tumor survivors. Infographic reviews late effects and survivorship care considerations for this pediatric kidney cancer population, addressing physical, cognitive, and endocrine sequelae of treatment.
Key takeaways
- Wilms tumor survivors average 12.7 health conditions by age 40, vs 4.2 in controls—lifelong surveillance is essential.
- Over half of survivors develop endocrine complications; 26% have cardiovascular issues requiring proactive screening.
- Abdominal radiation (59%) and doxorubicin (67%) drive late toxicity—tailor follow-up to treatment exposure.
- Physical and neurocognitive impairments are common; integrate functional assessments into survivorship care.
- St. Jude Lifetime Cohort data: comprehensive clinical evaluation reveals multisystem late effects in Wilms survivors.
Comments